Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Cascadia Commences First Drill Test of 1,065 g/t Gold Outcrop at Catch Property (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Shuttle Pharmaceuticals Holdings Inc
SHPH
Healthcare
Biotechnology
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer...
-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SHPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Feb 28, 2025 10:01am
Shuttle Pharma Provides Corporate Update and Reports 2024
Shuttle Pharma’s recent highlights include the following: Accelerated patient enrollment of the Company’s key Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma
...more
(10)
•••
MikeTester
X
Post by
MikeTester
on Jan 23, 2025 12:24am
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): A Disc
https://beyondspx.com/article/shuttle-pharmaceuticals-holdings-inc-nasdaqshph-a-discovery-stage-pharma-innovating-radiation-therapyLLM Commentary:Looks like SHPH is hanging on by a thread. Phase 2
...more
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Jan 22, 2025 12:36pm
Shuttle Pharma Reaches Milestone in Patient Enrollment...
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company
...more
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Dec 16, 2024 8:53am
GROUNDBREAKING CANCER TREATMENT A CONSIDERATION FOR FAMILY..
Strong Data from NIH Sponsored Clinical Trial Suggests Ropidoxuridine Could be Major Advancement for Cancer Patients and Big Win for Shuttle Pharmaceuticals’ Shareholders An estimated $7
...more
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Nov 27, 2024 9:19am
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinic
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company
...more
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Nov 14, 2024 3:36pm
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty
...more
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Oct 30, 2024 10:01am
SHPH Offering and Pays of Senior Debt
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty
...more
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Oct 29, 2024 11:58am
Shuttle Pharma Doses First Patients in Phase 2 Clinical ...
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company
...more
(10)
•••
AveragePenny
X
Post by
AveragePenny
on Oct 25, 2024 1:00pm
SHPH QUANTUM LEAP NEXT GENERATION CANCER RADIATION TREATMENT
Shuttle Pharmaceuticals’ Ropidoxuridine Could Substantially Increase Demand for Improved and Cost-Effective Cancer Radiation Treatments National Cancer Institute supported clinical trials
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 16, 2024 9:00am
New Press Release - Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 11, 2024 1:03pm
New Press Release - Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap Investor Summit Virtual 2024 Conference are now...
read article.
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 06, 2024 10:12am
SHPH..... $1.75 now
Done I rest my case
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 06, 2024 9:55am
SHPH...... This a.m low was $1.85
I'll say it now .... You've all been had ...... AGAIN !!!!!
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 05, 2024 12:33pm
SHPH....N.L.O.D $2.165
The worst is yet to come.....wait for it Sub $2 anyone???
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 05, 2024 10:42am
SHPH......Your all going to be screwed & Tattooed
Patent news is "Fluff"
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >